Evidence-based practice of prevention of cardiovascular pathology.

Evidence-based practice of prevention of cardiovascular pathology.

Prof. О.M. Korzh, G.I. PHD Kochuev, S.V. PHD Krasnokutskiy. Kharkiv Medical Academy of Postgraduate Education, Ukraine.

This paper deals with the position of evidence-based medicine principles of management of patients at high cardiovascular risk. In patients with multiple risk factors is insufficient impact on each factor separately, is required based on the principles of evidence-based integrated approach aimed. To ensure the effectiveness of this approach, it is necessary to summarize and discuss the evidence on which it is based. The possibilities of increasing the motivation of doctors and patients in reducing cardiovascular risk.

Key words: high cardiovascular risk, evidence-based medicine, therapeutic approaches.

Korzh ОM, Kochuev GI, Krasnokutskiy SV. [Evidence-based practice of prevention of cardiovascular pathology]. Shidnoevr. z. vnutr. simejnoi med. 2014;1:10-15. Russian.


1. Rosendorff C, Black HR, Cannon CP [Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention]. Circulation. 2007; 115: 2761—2788. English
2. Vickrey BG, Rector TS, Wickstrom SL [Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease]. Stroke. 2002; 33: 901—906. English
3. Yusuf S, Hawken S, Ounpuu S [Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study]. Lancet. 2004; 364: 937—952. English
4. Mancia G, Volpe R, Boros S [Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care]. I. Hypertens. 2004; 22: 51—57. English
5. Hobbs FD, Erhardt L [Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey]. Fam. Pract. 2002; 19: 596—604. English
6. Barrios V, Escobar C, Calderon A [Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONROLRISK Study]. I. Hum. Hypertens. 2007; 21: 479—485. English
7. Brindle P, Beswick A, Fahey T, Ebrahim S [Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review]. Heart. 2006; 92:1752—1759. English
8. Yusuf S, Teo KK, Pogue I [Telmisartan, ramipril, or both in patients at high risk of vascular events]. N. Engl. I. Med. 2008; 358:1547—1559. English
9. Cuspidi C, Ambrosioni E, Mancia G [Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the assessment of prognostic risk observational survey]. I. Hypertens. 2002; 20:1307— 1314. English
10. Erhardt L [Managing cardiovascular risk: reality vs. perception]. Eur. Heart I. 2005; 7: 111—115. English
11. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB [Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes]. Circulation. 2003; 107: 2435—2439. English
12. Mancia G, Backer DG, Dominiczak A, authors. [2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)]. I. Hypertens. 2007; 25: 1105—1187. English
13. Colhoun HM, Betteridge DI, Durrington PN [Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative Atorvastatin diabetes study (CARDS): multicentre randomized placebo-controlled trial]. Lancet. 2004; 364: 685—696. English
14. Collins R, Armitage I, Parish S [MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial]. Lancet. 2003; 361: 2005—2016. English
15. Snow V, Aronson MD, Hornbake ER [Lipid control in the management of type 2 diabetes mellitus]. Ann. Intern. Med. 2004; 140: 644—649. English
16. Unger T, Stoppelhaar M [Rationale for double rennin-angiotensinaldosterone system blockade]. Am. I. Cardiol. 2007; 100: 25I—31I. English
17. Antithrombotic Trialists Collaboration. [Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients]. BMI. 2002; 324:71—86. English
18. Harmon G, Lefante I, Krousel-Wood M. [Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications]. Curr. Opin. Cardiol. 2006; 21: 310—315. English
19. Nissen SE, Tardif IC, Nicholls SI. [Effect of torcetrapib on the progression of coronary atherosclerosis]. N. Engl. I. Med. 2007; 356: 1304—1316. English
20. Backlund L, Bring I, Strender LE [How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?]. Prim. Health Care Res. Dev. 2004; 5: 145—152. English
21. Tabor PA, Lopez DA. [Comply with us: improving medication adherence]. I. Pharm. Pract. — 2004; 17: 167—181. English
22. Osterberg L, Blaschke T. [Adherence to medication]. N. Engl. I. Med. 2005; 353: 487—497. English